Tyligand Bioscience
Innovative small molecule therapeutics for cancer and autoimmune disease treatment.
Innovative small molecule therapeutics for cancer and autoimmune disease treatment.
Tyligand Bioscience is a biotechnology company founded in 2018 with a focus on developing innovative small molecule therapeutics for cancer and autoimmune disease treatment. Their commitment to discovering and developing small molecule therapeutics has attracted significant investment, with the latest being a Series A investment on 08 July 2023. This round of funding was led by a consortium of investors including Calor Capital, Shengdi Investment, YF Capital, TaiKun Fund, Ming Bioventures, BOHE Angel Fund, CMS Capital. Tyligand Bioscience's unique approach and potential for impact in the biotechnology and healthcare industries have garnered notable attention from venture capital firms. Their mission to develop effective treatments for tumors and autoimmune disorders signifies a promising future in the field of healthcare innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 7 |
|
08 Jul 2023 |
| Seed Round | Unknown | 1 |
|
01 Jan 2020 |
No recent news or press coverage available for Tyligand Bioscience.
We care about your data, and we'd love to use cookies make your experience better.
